# Hensin Tsao

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3450788/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 114 papers | 7,529 citations | 76326 40 h-index | 53230 85 g-index |
| 116 all docs | 116 docs citations | 116 times ranked | 9524 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Factors associated with suspected nonmelanoma skin cancers, dysplastic nevus, and cutaneous melanoma among first-time SpotMe screening program participants during 2009-2010. Journal of the American Academy of Dermatology, 2023, 88, 60-70. | 1.2 | 6 |
| 2 | Oncogenic KIT Induces Replication Stress and Confers Cell Cycle Checkpoint Vulnerability in Melanoma. Journal of Investigative Dermatology, 2022, 142, 1413-1424.e6. | 0.7 | 3 |
| 3 | A geographically based cross-sectional analysis of SPOT me skin cancer screening data. Journal of the American Academy of Dermatology, 2021, 84, 809-810.e3. | 1.2 | 0 |
| 4 | Surgical delay and mortality for primary cutaneous melanoma. Journal of the American Academy of Dermatology, 2021, 84, 1089-1091. | 1.2 | 8 |
| 5 | The State of Melanoma: Emergent Challenges and Opportunities. Clinical Cancer Research, 2021, 27, 2678-2697. | 7.0 | 53 |
| 6 | Patient-identified early clinical warning signs of nodular melanoma: a qualitative study. BMC Cancer, 2021, 21, 371. | 2.6 | 5 |
| 7 | Loss of ACK1 Upregulates EGFR and Mediates Resistance to BRAF Inhibition. Journal of Investigative Dermatology, 2021, 141, 1317-1324.e1. | 0.7 | 9 |
| 8 | The spectrum of morphologic patterns of nodular melanoma: a study of the International Dermoscopy Society. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e762-e765. | 2.4 | 4 |
| 9 | Melanoma genomics: a stateâ€ofâ€theâ€art review of practical clinical applications*. British Journal of Dermatology, 2021, 185, 272-281. | 1.5 | 12 |
| 10 | Recognition, Staging, and Management of Melanoma. Medical Clinics of North America, 2021, 105, 643-661. | 2.5 | 4 |
| 11 | Germline ATM variants predispose to melanoma: a joint analysis across the GenoMEL and MelaNostrum consortia. Genetics in Medicine, 2021, 23, 2087-2095. | 2.4 | 19 |
| 12 | Melanoma medicine in the new millennium. British Journal of Dermatology, 2021, 185, 239-240. | 1.5 | 0 |
| 13 | The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma. Journal of Investigative Dermatology, 2021, 141, 2018-2027.e4. | 0.7 | 8 |
| 14 | Effect of the COVID-19 Pandemic on Delayed Skin Cancer Services. Dermatologic Clinics, 2021, 39, 627-637. | 1.7 | 21 |
| 15 | Unsupervised Phenotype-Based Clustering of Clinicopathologic Features in Cutaneous Melanoma. JID Innovations, 2021, 1, 100047. | 2.4 | 1 |
| 16 | Abstract P117: Oncogenic Kit induces replication stress and induces Chk1/ATR inhibitor sensitivity in melanoma. , 2021, , . | | 0 |
| 17 | Number needed to screen for presumptive screening diagnoses among first-time SPOTme screening participants (1992-2010). Journal of the American Academy of Dermatology, 2020, 82, 233-234. | 1.2 | 3 |
| 18 | Classifying Melanoma by TERT Promoter Mutational Status. Journal of Investigative Dermatology, 2020, 140, 390-394.e1. | 0.7 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Consensus, Controversy, and Conversations About Gene Expression Profiling in Melanoma. JAMA Dermatology, 2020, 156, 949. | 4.1 | 6 |
| 20 | Cancer risks associated with the germline MITF(E318K) variant. Scientific Reports, 2020, 10, 17051. | 3.3 | 20 |
| 21 | Hypoxia and HIF-1Î± Regulate Collagen Production in Keloids. Journal of Investigative Dermatology, 2020, 140, 2157-2165. | 0.7 | 39 |
| 22 | KIT and Melanoma: Biological Insights and Clinical Implications. Yonsei Medical Journal, 2020, 61, 562. | 2.2 | 67 |
| 23 | The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma. Cell Reports, 2019, 27, 3573-3586.e7. | 6.4 | 66 |
| 24 | BRCA1â€associated protein (BAP1)â€inactivated melanocytic tumors. Journal of Cutaneous Pathology, 2019, 46, 965-972. | 1.3 | 38 |
| 25 | Burden of unique and low prevalence somatic mutations correlates with cancer survival. Scientific Reports, 2019, 9, 4848. | 3.3 | 49 |
| 26 | Caseâ€“control analysis identifies shared properties of rare germline variation in cancer predisposing genes. European Journal of Human Genetics, 2019, 27, 824-828. | 2.8 | 4 |
| 27 | Use of Targeted Next-Generation Sequencing to Identify Activating Hot Spot Mutations in Cherry Angiomas. JAMA Dermatology, 2019, 155, 211. | 4.1 | 22 |
| 28 | Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma. Oncogene, 2019, 38, 3504-3520. | 5.9 | 11 |
| 29 | Guidelines of care for the management of primary cutaneous melanoma. Journal of the American Academy of Dermatology, 2019, 80, 208-250. | 1.2 | 400 |
| 30 | Clinical spectrum of cutaneous melanoma morphology. Journal of the American Academy of Dermatology, 2019, 80, 178-188.e3. | 1.2 | 21 |
| 31 | A Case of Nivolumab-Induced Cutaneous Toxicity with Multiple Morphologies. Dermatopathology (Basel, Switzerland), 2019, 6, 255-259. | 1.5 | 9 |
| 32 | Selective uveal melanoma inhibition with calcium channel blockade. International Journal of Oncology, 2019, 55, 1090-1096. | 3.3 | 10 |
| 33 | Contrasting features of childhood and adolescent melanomas. Pediatric Dermatology, 2018, 35, 354-360. | 0.9 | 26 |
| 34 | High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma. Journal of Investigative Dermatology, 2018, 138, 1582-1590. | 0.7 | 46 |
| 35 | Cutaneous Presentation of Mesothelioma With a Sarcomatoid Transformation. American Journal of Dermatopathology, 2018, 40, 378-382. | 0.6 | 3 |
| 36 | Comprehensive Study of the Clinical Phenotype of GermlineBAP1Variant-Carrying Families Worldwide. Journal of the National Cancer Institute, 2018, 110, 1328-1341. | 6.3 | 164 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | The first 30Âyears of the American Academy of Dermatology skin cancer screening program: 1985-2014. Journal of the American Academy of Dermatology, 2018, 79, 884-891.e3. | 1.2 | 46 |
| 38 | Recent Advances in Melanoma and Melanocyte Biology. Journal of Investigative Dermatology, 2017, 137, 557-560. | 0.7 | 12 |
| 39 | Introduction to JIDâ€™s Landmarks inÂtheÂMolecular Revolution. Journal of Investigative Dermatology, 2017, 137, 996. | 0.7 | 0 |
| 40 | Somatic driver mutations in melanoma. Cancer, 2017, 123, 2104-2117. | 4.1 | 96 |
| 41 | Rare Variant, Gene-Based Association Study of Hereditary Melanoma Using Whole-Exome Sequencing. Journal of the National Cancer Institute, 2017, 109, . | 6.3 | 32 |
| 42 | Cutaneous melanoma in women. International Journal of Women's Dermatology, 2017, 3, S11-S15. | 2.0 | 29 |
| 43 | Genotypic and Phenotypic Features of BAP1 Cancer Syndrome. JAMA Dermatology, 2017, 153, 999. | 4.1 | 86 |
| 44 | Epidemiology of Melanoma. , 2017, , 591-611. | | 2 |
| 45 | Betaâ€catenin causes fibrotic changes in the extracellular matrix via upregulation of collagen I transcription. British Journal of Dermatology, 2017, 177, 312-315. | 1.5 | 10 |
| 46 | Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients. American Journal of Cancer Research, 2017, 7, 134-138. | 1.4 | 6 |
| 47 | In vivo coherent Raman imaging of the melanomagenesis-associated pigment pheomelanin. Scientific Reports, 2016, 6, 37986. | 3.3 | 33 |
| 48 | Defining Clonal Color in Fluorescent Multi-Clonal Tracking. Scientific Reports, 2016, 6, 24303. | 3.3 | 10 |
| 49 | Reply to: â€œThe absence of multiple atypical nevi in germline CDKN2A mutationsâ€• Journal of the American Academy of Dermatology, 2016, 75, e159. | 1.2 | 0 |
| 50 | New Insights into the Molecular Distinction of Dysplastic Nevi and Common Melanocytic Neviâ€”Highlighting the Keratinocyte-Melanocyte Relationship. Journal of Investigative Dermatology, 2016, 136, 1933-1935. | 0.7 | 4 |
| 51 | Visual Inspection and the US Preventive Services Task Force Recommendation on Skin Cancer Screening. JAMA - Journal of the American Medical Association, 2016, 316, 398. | 7.4 | 18 |
| 52 | The state of melanoma: challenges and opportunities. Pigment Cell and Melanoma Research, 2016, 29, 404-416. | 3.3 | 77 |
| 53 | Hereditary melanoma: Update on syndromes and management. Journal of the American Academy of Dermatology, 2016, 74, 411-420. | 1.2 | 60 |
| 54 | Hereditary melanoma: Update on syndromes and management. Journal of the American Academy of Dermatology, 2016, 74, 395-407. | 1.2 | 158 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival. Journal of Investigative Dermatology, 2016, 136, 1002-1011. | 0.7 | 51 |
| 56 | A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors. Cancer Biology and Therapy, 2016, 17, 778-784. | 3.4 | 8 |
| 57 | Genetics of melanocytic nevi. Pigment Cell and Melanoma Research, 2015, 28, 661-672. | 3.3 | 135 |
| 58 | Melanoma-associated naevi: precursors or coincidence?. British Journal of Dermatology, 2015, 173, 633-634. | 1.5 | 2 |
| 59 | Concerns About Presence of a Wild-TypeBAP1Allele in Absence of Nuclear Protein Expressionâ€"Reply. JAMA Dermatology, 2015, 151, 1266. | 4.1 | 0 |
| 60 | A recurrent germline <scp>BAP1</scp> mutation and extension of the <scp>BAP1</scp> tumor predisposition spectrum to include basal cell carcinoma. Clinical Genetics, 2015, 88, 267-272. | 2.0 | 81 |
| 61 | Clinical Significance of Microscopic Melanoma Metastases in the Nonhottest Sentinel Lymph Nodes. JAMA Surgery, 2015, 150, 465. | 4.3 | 9 |
| 62 | Cutaneous melanoma in women. International Journal of Women's Dermatology, 2015, 1, 21-25. | 2.0 | 12 |
| 63 | EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma. Cancer Discovery, 2015, 5, 274-287. | 9.4 | 107 |
| 64 | Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapyâ€"Mediated Metastatic Melanoma Phenotype. Cancer Discovery, 2015, 5, 264-273. | 9.4 | 82 |
| 65 | Reply to: â€œThe ABCDs of melanomaâ€"A complicated morphologic message not intended for the general publicâ€• Journal of the American Academy of Dermatology, 2015, 73, e61. | 1.2 | 0 |
| 66 | Targeted Therapies in Melanoma: Translational Research at Its Finest. Journal of Investigative Dermatology, 2015, 135, 1929-1933. | 0.7 | 12 |
| 67 | Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanoma. Melanoma Management, 2015, 2, 133-147. | 0.5 | 3 |
| 68 | MITF Modulates Therapeutic Resistance through EGFR Signaling. Journal of Investigative Dermatology, 2015, 135, 1863-1872. | 0.7 | 76 |
| 69 | Multiple Cutaneous Melanomas and Clinically Atypical Moles in a Patient With a Novel GermlineBAP1Mutation. JAMA Dermatology, 2015, 151, 1235. | 4.1 | 20 |
| 70 | Gender Disparity and Mutation Burden in Metastatic Melanoma. Journal of the National Cancer Institute, 2015, 107, djv221. | 6.3 | 114 |
| 71 | BAP1 Has a Survival Role in Cutaneous Melanoma. Journal of Investigative Dermatology, 2015, 135, 1089-1097. | 0.7 | 31 |
| 72 | Outcome of patients with de novo versus nevus-associated melanoma. Journal of the American Academy of Dermatology, 2015, 72, 54-58. | 1.2 | 71 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget, 2015, 6, 12297-12309. | 1.8 | 148 |
| 74 | Epidermal, Sebaceous, and Melanocytic Nevoid Proliferations Are Spectrums of Mosaic RASopathies. Journal of Investigative Dermatology, 2014, 134, 2493-2496. | 0.7 | 21 |
| 75 | Opening the melanoma black box. British Journal of Dermatology, 2014, 170, 9-10. | 1.5 | 0 |
| 76 | Melanoma: Clinical Features and Genomic Insights. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a015388-a015388. | 6.2 | 42 |
| 77 | The utility of re-excising mildly and moderately dysplastic nevi: A retrospective analysis. Journal of the American Academy of Dermatology, 2014, 71, 1071-1076. | 1.2 | 31 |
| 78 | Melanocytes Are Selectively Vulnerable to UVA-Mediated Bystander Oxidative Signaling. Journal of Investigative Dermatology, 2014, 134, 1083-1090. | 0.7 | 24 |
| 79 | Commentary: Molecular testing in melanoma. Journal of the American Academy of Dermatology, 2014, 70, 863-870. | 1.2 | 4 |
| 80 | Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma. Seminars in Cutaneous Medicine and Surgery, 2014, 33, 60-67. | 1.6 | 20 |
| 81 | Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and Suppresses Melanoma Viability and Tumor Growth. Clinical Cancer Research, 2013, 19, 4383-4391. | 7.0 | 33 |
| 82 | p53 Rescue through HDM2 Antagonism Suppresses Melanoma Growth and Potentiates MEK Inhibition. Journal of Investigative Dermatology, 2012, 132, 356-364. | 0.7 | 66 |
| 83 | Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma. Clinical Cancer Research, 2012, 18, 4026-4036. | 7.0 | 96 |
| 84 | Melanoma: from mutations to medicine. Genes and Development, 2012, 26, 1131-1155. | 5.9 | 415 |
| 85 | A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature, 2011, 480, 99-103. | 27.8 | 413 |
| 86 | Case 30-2010. New England Journal of Medicine, 2010, 363, 1352-1360. | 27.0 | 0 |
| 87 | Melanoma Genetics and Therapeutic Approaches in the 21st Century: Moving from the Benchside to the Bedside. Journal of Investigative Dermatology, 2008, 128, 2575-2595. | 0.7 | 157 |
| 88 | Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Human Mutation, 2007, 28, 578-588. | 2.5 | 222 |
| 89 | High-risk Melanoma Susceptibility Genes and Pancreatic Cancer, Neural System Tumors, and Uveal Melanoma across GenoMEL. Cancer Research, 2006, 66, 9818-9828. | 0.9 | 373 |
| 90 | Expression Profiling of UVB Response in Melanocytes Identifies a Set of p53-Target Genes. Journal of Investigative Dermatology, 2006, 126, 2490-2506. | 0.7 | 86 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | The SNPs of RAF. Journal of Investigative Dermatology, 2005, 125, xiv-xv. | 0.7 | 1 |
| 92 | Melanoma Treatment Update. Dermatologic Clinics, 2005, 23, 323-333. | 1.7 | 23 |
| 93 | Case 7-2004. New England Journal of Medicine, 2004, 350, 924-932. | 27.0 | 9 |
| 94 | Early Detection of Asymptomatic Pulmonary Melanoma Metastases by RoutineChest Radiographs Is Not Associated With Improved Survival. Archives of Dermatology, 2004, 140, 67-70. | 1.4 | 45 |
| 95 | Genetic Interaction Between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma. Journal of Investigative Dermatology, 2004, 122, 337-341. | 0.7 | 411 |
| 96 | Management of Cutaneous Melanoma. New England Journal of Medicine, 2004, 351, 998-1012. | 27.0 | 735 |
| 97 | PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma. Journal of the American Academy of Dermatology, 2003, 49, 865-872. | 1.2 | 103 |
| 98 | The Transformation Rate of Moles (Melanocytic Nevi) Into Cutaneous Melanoma. Archives of Dermatology, 2003, 139, 282. | 1.4 | 282 |
| 99 | Cutaneous Melanomas Associated With Nevi. Archives of Dermatology, 2003, 139, 1620. | 1.4 | 224 |
| 100 | A single-institution case series of patients with cutaneous melanoma and non-Hodgkin's lymphoma. Journal of the American Academy of Dermatology, 2002, 46, 55-61. | 1.2 | 15 |
| 101 | Hypopigmentation Associated With an Adenovirus-Mediated gp100/MART-1â€“Transduced Dendritic Cell Vaccine for Metastatic Melanoma. Archives of Dermatology, 2002, 138, 799-802. | 1.4 | 42 |
| 102 | Evidence for an association between cutaneous melanoma and non-Hodgkin lymphoma. Cancer, 2001, 91, 874-880. | 4.1 | 61 |
| 103 | A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma. Archives of Dermatology, 2001, 137, 325-30. | 1.4 | 39 |
| 104 | Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Research, 2000, 60, 1800-4. | 0.9 | 185 |
| 105 | Update on familial cancer syndromes and the skin. Journal of the American Academy of Dermatology, 2000, 42, 939-69; quiz 970-2. | 1.2 | 11 |
| 106 | Mutational and expression analysis of the p73 gene in melanoma cell lines. Cancer Research, 1999, 59, 172-4. | 0.9 | 34 |
| 107 | American Academy of Dermatology 1999 Awards for Young Investigators in Dermatology. Targets of genetic injury in cutaneous melanoma. Journal of the American Academy of Dermatology, 1999, 41, 459-61. | 1.2 | 0 |
| 108 | Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene, 1998, 16, 3397-3402. | 5.9 | 224 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene. Cancer Research, 1998, 58, 109-13. | 0.9 | 56 |
| 110 | Epithelioid Sarcoma Presenting as a Benign Foot Ulcer. Journal of Cutaneous Medicine and Surgery, 1997, 1, 232-234. | 1.2 | 0 |
| 111 | Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer, 1997, 79, 2361-2370. | 4.1 | 142 |
| 112 | Lack of phospholipase A2 mutations in neuroblastoma, melanoma and colon-cancer cell lines. , 1997, 72, 337-339. | | 16 |
| 113 | Ultraâ€late recurrence (15 years or longer) of cutaneous melanoma. Cancer, 1997, 79, 2361-2370. | 4.1 | 5 |
| 114 | Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer, 1997, 79, 2361-70. | 4.1 | 32 |